MNG1078
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.268
- E2F_TARGETS+0.189
- SPERMATOGENESIS+0.157
- G2M_CHECKPOINT+0.118
- OXIDATIVE_PHOSPHORYLATION+0.102
- MYOGENESIS+0.069
- PANCREAS_BETA_CELLS+0.054
- KRAS_SIGNALING_UP+0.051
- HEDGEHOG_SIGNALING+0.023
- MYC_TARGETS_V2+0.016
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.570
- PROTEIN_SECRETION-0.531
- MYC_TARGETS_V1-0.425
- INTERFERON_GAMMA_RESPONSE-0.418
- ANDROGEN_RESPONSE-0.411
- UV_RESPONSE_DN-0.389
- APOPTOSIS-0.383
- FATTY_ACID_METABOLISM-0.358
- PEROXISOME-0.355
- UNFOLDED_PROTEIN_RESPONSE-0.339
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.268 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.189 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.157 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.118 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.102 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.069 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.054 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.051 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.023 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.016 | Idelalisib | — uncovered |